Eligibility NCT00534287 Severe Sepsis Inclusion Criteria Exclusion Criteria Age <18 years Yes
No
Pregnancy, Gestation Yes
No
Breast feeding, Nursing Yes
No
Pretreatment with meropenem, imipenem, or ertapenem within the last 4 weeks (>1 daily dosage) Yes
No
Pretreatment with moxifloxacin,ciprofloxacin, or levofloxacin within the last 4 weeks (>1 daily dosage) Yes
No
Pretreatment with a pseudomonas effective cephalosporin (cefepime, ceftazidim, cefpirom) or piperacillin within the last 48 hours (>1 daily dosage). Yes
No
Pretreatment with other chinolones within the last 4 weeks (>1 daily dosage) Yes
No
Presence of infection where guidelines recommend another antimicrobial therapy than the study medication (i.e. endocarditis) Yes
No
Evidence or strong clinical suspicion of a microorganism where the study medication is known to be ineffective (i.e. tuberculosis, MRSA- or VRE-infection) Yes
No
Known allergy against meropenem or moxifloxacin Yes
No
Tendon disease or injury due to past quinolone therapy Yes
No
Congenital or acquired prolongation of QT-interval Yes
No
Concomitant medication which prolongs the QT-interval Yes
No
Electrolyte imbalance, especially uncorrected hypokalemia Yes
No
Clinically relevant bradycardia Yes
No
Clinically relevant cardiac dysfunction with reduced left-ventricular ejection fraction Yes
No
Symptomatic arrhythmias in the medical history Yes
No
Significant hepatic impairment (Child-Pugh C) or elevation of liver enzymes >5x the upper normal range Yes
No
No commitment to full patient support (i.e. DNR order) Yes
No
Patient's death is considered imminent due to coexisting disease Yes
No
Concomitant participation in another study or study participation within the last 30 days. Yes
No
Relationship of the patient to study team member (i.e. colleague, relative) Yes
No
